Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Crawford, J ^a   Caserta, C ^b   Roila, F ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b S MARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE; PACLITAXEL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TOPOTECAN; VINBLASTINE; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AXILLA TEMPERATURE; BLADDER CANCER; BREAST CANCER; CANCER RADIOTHERAPY; DISEASE DURATION; EUROPE; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEDICAL SOCIETY; MORTALITY; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SARCOMA; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; STOMACH CANCER; TESTIS CANCER; TREATMENT INDICATION; UTERINE CERVIX CANCER;

EUROPE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; INCIDENCE; INTERLEUKIN-3; NEUTROPENIA;

EID: 77954335295     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq195     Document Type: Article

References (18)

1. Vogel CL, Wojtukiewicz MZ, Carroll RR et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005; 23: 1178-1184.
2. Timmer-Bonte JN, de Boo TM, Smith HJ et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 2005; 23: 7974-7984.
3. ASCO Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-2508.
4. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
5. Cheng AC, Stephens DP, Currie BJ. Granulocyte colony stimulating factor (GCSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 2003; issue 4: CD004400.
6. Sung L, Nathan PC, Alibhai SMH et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infections. Ann Intern Med 2007; 147: 400-411.
7. Kuderer NM, Dale DC, Crawford J et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor in febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25: 3158-3167.
8. Hershman D, Neugut AI, Jacobson JS et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99: 196-205.
9. Schmitz N, Ljungman P, Cordonnier C et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplant 2004; 34: 955-962.
10. Green MD, Koelbl H, Baselga J et al. International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
11. Holmes FA, O'Shaughnessy JA, Vukelja S et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
12. Relling MV, Boyett JM, Blanco JG et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101: 3862-3867.
13. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
14. Waselenko JK, MacVittie TJ, Blakely WF et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 2004; 140: 1037-1051.
15. Kouroukis CT, Chia S, Verma S et al. Canadian supportive care recommendations for the management of neutropenia in patients with cancer. Curr Oncol 2008; 15: 9-23.
16. Zielinski CC, Awada A, Cameron DA et al. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. Eur J Cancer 2008; 44: 353-365.
17. Liu MC, Demetri GD, Berry DA et al. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev 2008; 34: 223-230.
18. Skoetz N, Weingart O, Monsef I. Ninth Biannual Report of the Cochrane Haematological Malignancies Group-Focus on Hematopoietic Growth Factors. J Natl Cancer Inst 2009; 101: E1. Epub 2009 Apr 28. PMID: 19401542.